Skip to main content
REGENERON PHARMACEUTICALS, INC. logo

REGENERON PHARMACEUTICALS, INC. — Investor Relations & Filings

Ticker · REGN ISIN · US75886F1075 LEI · 549300RCBFWIRX3HYQ56 US Manufacturing
Filings indexed 1,720 across all filing types
Latest filing 2022-11-03 Director's Dealing
Country US United States of America
Listing US REGN

About REGENERON PHARMACEUTICALS, INC.

https://www.regeneron.com/

Regeneron Pharmaceuticals, Inc. is an integrated biotechnology company that invents, develops, manufactures, and commercializes medicines for serious diseases. The company's research and development efforts are focused on a wide range of therapeutic areas, including ophthalmology, cancer, allergic and inflammatory diseases, cardiovascular and metabolic disorders, and rare diseases. Regeneron leverages its expertise in biologics and genetic medicines to translate scientific breakthroughs into transformative treatments for patients.

Recent filings

Filing Released Lang Actions
PRIMARY DOCUMENT
Director's Dealing
2022-11-03 English
10-Q
Interim / Quarterly Report Q3 2022
2022-11-03 English
8-K
Earnings Release Classification · 95% confidence The document is a Form 8-K filed with the SEC, dated November 3, 2022, reporting the issuance of a press release announcing financial and operating results for the quarter ended September 30, 2022. The text explicitly states that the press release is furnished as Exhibit 99.1 and is incorporated by reference. The document itself does not contain detailed financial statements or substantive financial data but rather serves as a current report to announce the earnings release. The length is 3636 characters, which is relatively short and consistent with an earnings release announcement rather than a full report. According to the classification rules, such a document announcing quarterly financial results is best classified as an Earnings Release (ER).
2022-11-03 English
PRIMARY DOCUMENT
Director's Dealing
2022-11-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-11-02 English
PRIMARY DOCUMENT
Director's Dealing
2022-10-18 English

Report missing filing

Can't find a specific document? Let us know and we'll add it within 24 hours.

We will notify you once the filing is added.
Report sent
Thank you. We will check the data and update it shortly.